Hangzhou AGS MedTech Co. Ltd. A (688581) - Total Assets
Based on the latest financial reports, Hangzhou AGS MedTech Co. Ltd. A (688581) holds total assets worth CN¥2.70 Billion CNY (≈ $394.83 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hangzhou AGS MedTech Co. Ltd. A - Total Assets Trend (2021–2025)
This chart illustrates how Hangzhou AGS MedTech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. Also see 688581 company net worth for the company's overall valuation and market capitalisation.
Hangzhou AGS MedTech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Hangzhou AGS MedTech Co. Ltd. A's total assets of CN¥2.70 Billion consist of 78.2% current assets and 21.8% non-current assets. Review Hangzhou AGS MedTech Co. Ltd. A total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 44.0% |
| Accounts Receivable | CN¥54.41 Million | 2.0% |
| Inventory | CN¥59.65 Million | 2.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥48.45 Million | 1.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Hangzhou AGS MedTech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hangzhou AGS MedTech Co. Ltd. A share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou AGS MedTech Co. Ltd. A's current assets represent 78.2% of total assets in 2025, an increase from 76.8% in 2021.
- Cash Position: Cash and equivalents constituted 44.0% of total assets in 2025, down from 59.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 5.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 2.2% of total assets.
Hangzhou AGS MedTech Co. Ltd. A Competitors by Total Assets
Key competitors of Hangzhou AGS MedTech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
COPLAND ROAD CAPITAL NEW
F:A2P
|
Germany | €605.37 Million |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Shanghai Kinetic Medical Co
SHE:300326
|
China | CN¥3.38 Billion |
Hangzhou AGS MedTech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.48 | 20.59 | 22.61 |
| Quick Ratio | 17.03 | 19.93 | 22.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.97 Billion | CN¥1.81 Billion | CN¥2.04 Billion |
Hangzhou AGS MedTech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Hangzhou AGS MedTech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | CN¥2.68 Billion |
| Market Capitalization | $602.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou AGS MedTech Co. Ltd. A's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hangzhou AGS MedTech Co. Ltd. A's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
The table below shows the annual total assets of Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.68 Billion ≈ $391.68 Million |
+4.98% |
| 2024-12-31 | CN¥2.55 Billion ≈ $373.11 Million |
+9.38% |
| 2023-12-31 | CN¥2.33 Billion ≈ $341.11 Million |
+392.69% |
| 2022-12-31 | CN¥473.13 Million ≈ $69.23 Million |
+38.34% |
| 2021-12-31 | CN¥341.99 Million ≈ $50.04 Million |
-- |
About Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic instruments in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; an… Read more